Clinical trial of trans sodium crocetinate against COVID-19

Phase 2

• Conditions: Covid-19.; COVID-19 Disease; U07.1

• Registration Number: IRCT20081019001369N6
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 15 June 2020

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Patients with clinical diagnosis for Covid-19 disease,
Patients with acute respiratory distress syndrome (ARDS),
Patients not having kidney, liver and heart dysfunction according to clinical and laboratory findings
PF ratio (the ratio of arterial oxygen partial pressure to fractional inspired oxygen) <300 ,

Exclusion Criteria

Allergic reactions to saffron
Pregnancy or breast-feeding
Multi organ dysfunction disease

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Patients' mortality rate. Timepoint: During 7 days hospitalization. Method of measurement: Meedical Reports.

Secondary Outcome Measures

Name	Time	Method
Days under ventilation. Timepoint: During 7 days hospitalization. Method of measurement: Meedical Reports.;Hospitalization days in ICU. Timepoint: During 7 days hospitalization. Method of measurement: Medical Report.;Getting multi organ dysfunction. Timepoint: During 7 days hospitalization. Method of measurement: Clinical and laboratory evaluation.;Improving PF ration. Timepoint: daily during 7 days hospitalization. Method of measurement: ratio calculated from PaO2/FiO2.;Improving Sofa (The sequential organ failure assessment ) score. Timepoint: the first day and during 7 days hospitalization. Method of measurement: According to clinical and laboratory evaluation.